翰宇藥業(300199.SZ)2022年度預虧3.3億-3.8億元、HY3000鼻噴霧劑等多個創新藥項目穩步推進
格隆匯1月17日丨翰宇藥業(300199.SZ)公佈,預計2022年度歸屬於上市公司股東的淨虧損3.3億元-3.8億元,上年同期為盈利3080.78萬元;扣除非經常性損益後淨虧損2.8億元-3.3億元,上年同期為虧損39996.99萬元。
業績變動原因如下:
1、報吿期內,公司HY3000鼻噴霧劑等多個創新藥項目穩步推進,本期研發投入較上期有所增加導致公司研發費用上升,對公司2022年度利潤產生影響。
2、2021年度,公司將持有的健麾信息股權由長期股權投資核算變更為按交易性金融資產核算產生投資收益約3.77億元,本期無相關事項。此外,本期因健麾信息股權股價下跌產生公允價值變動損失約0.7億元。
公司預計2022年全年非經常性損益對淨利潤的影響金額約-0.53億元,主要是為持有健麾信息股權產生的公允價值變動損失。去年同期非經常性損益金額為4.31億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.